Lupus

Papers
(The H4-Index of Lupus is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends80
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression77
10 Years of belimumab experience: What have we learnt?53
Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint45
Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort43
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus36
Inflammatory myositis in systemic lupus erythematosus28
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry28
Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus27
16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome26
16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome26
Predictive value of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-neutrophil ratio, and neutrophil-to-monocyte ratio in lupus nephritis26
Syk inhibitor attenuates inflammation in lupus mice from FcgRIIb deficiency but not in pristane induction: the influence of lupus pathogenesis on the therapeutic effect25
Systemic lupus erythematosus: The search for the ideal biomarker24
Systemic lupus erythematosus–associated diffuse alveolar hemorrhage: a single-center, matched case–control study in China22
SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus22
Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK22
Immune thrombocytopenia and COVID-19: Case report and review of literature22
Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort21
Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort21
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)20
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus20
Lupus, vaccinations and COVID-19: What we know now20
0.029778003692627